PL1742644T3 - Kompozycja terapeutyczna zawierająca co najmniej jedną pochodną pirolobenzodiazepiny i fludarabiny - Google Patents

Kompozycja terapeutyczna zawierająca co najmniej jedną pochodną pirolobenzodiazepiny i fludarabiny

Info

Publication number
PL1742644T3
PL1742644T3 PL05762344T PL05762344T PL1742644T3 PL 1742644 T3 PL1742644 T3 PL 1742644T3 PL 05762344 T PL05762344 T PL 05762344T PL 05762344 T PL05762344 T PL 05762344T PL 1742644 T3 PL1742644 T3 PL 1742644T3
Authority
PL
Poland
Prior art keywords
fludarabine
compositions containing
therapeutic compositions
pyrrolobenzodiazepine derivative
pyrrolobenzodiazepine
Prior art date
Application number
PL05762344T
Other languages
English (en)
Inventor
Patrick Delavault
Chris Pepper
Original Assignee
Ipsen Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma filed Critical Ipsen Pharma
Publication of PL1742644T3 publication Critical patent/PL1742644T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL05762344T 2004-04-27 2005-04-26 Kompozycja terapeutyczna zawierająca co najmniej jedną pochodną pirolobenzodiazepiny i fludarabiny PL1742644T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0404424A FR2869231B1 (fr) 2004-04-27 2004-04-27 Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
EP05762344A EP1742644B1 (fr) 2004-04-27 2005-04-26 Composition thérapeutique contenant au moins un dérivé de la pyrrolobenzodiazépine et la fludarabine
PCT/FR2005/001025 WO2005105113A2 (fr) 2004-04-27 2005-04-26 Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine

Publications (1)

Publication Number Publication Date
PL1742644T3 true PL1742644T3 (pl) 2012-05-31

Family

ID=34947843

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05762344T PL1742644T3 (pl) 2004-04-27 2005-04-26 Kompozycja terapeutyczna zawierająca co najmniej jedną pochodną pirolobenzodiazepiny i fludarabiny

Country Status (14)

Country Link
US (1) US8034808B2 (pl)
EP (1) EP1742644B1 (pl)
JP (1) JP5046922B2 (pl)
AT (1) ATE538801T1 (pl)
CA (1) CA2564603C (pl)
CY (1) CY1112387T1 (pl)
DK (1) DK1742644T3 (pl)
ES (1) ES2377066T3 (pl)
FR (1) FR2869231B1 (pl)
NO (1) NO338380B1 (pl)
PL (1) PL1742644T3 (pl)
PT (1) PT1742644E (pl)
SI (1) SI1742644T1 (pl)
WO (1) WO2005105113A2 (pl)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2869231B1 (fr) 2004-04-27 2008-03-14 Sod Conseils Rech Applic Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
GB0410725D0 (en) * 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
DE102008050988A1 (de) * 2008-09-01 2010-03-04 Gerd Reime Identifikationselement mit einem optischen Transponder
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
ES2623057T3 (es) 2010-04-15 2017-07-10 Medimmune Limited Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas
KR101772354B1 (ko) 2010-04-15 2017-08-28 시애틀 지네틱스, 인크. 표적화된 피롤로벤조디아제핀 접합체
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
WO2013041606A1 (en) 2011-09-20 2013-03-28 Spirogen Sàrl Pyrrolobenzodiazepines as unsymmetrical dimeric pbd compounds for inclusion in targeted conjugates
US9526798B2 (en) 2011-10-14 2016-12-27 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
MX358757B (es) 2011-10-14 2018-09-03 Seattle Genetics Inc Pirrolobenzodiazepinas y conjugados dirigidos.
BR112014008888A2 (pt) 2011-10-14 2017-04-18 Seattle Genetics Inc pirrolobenzodiazepinas
US9388187B2 (en) 2011-10-14 2016-07-12 Medimmune Limited Pyrrolobenzodiazepines
KR102099073B1 (ko) 2012-02-24 2020-04-10 애브비 스템센트알엑스 엘엘씨 항 ｓｅｚ6 항체들 및 사용 방법
EP3093294A1 (en) 2012-02-24 2016-11-16 Stemcentrx, Inc. Dll3 modulators and methods of use
KR101645905B1 (ko) 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
HRP20181646T2 (hr) 2012-10-12 2019-08-09 Adc Therapeutics Sa Konjugati pirolobenzodiazepin - anti-psma protutijela
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
AU2013328673B2 (en) 2012-10-12 2017-07-13 Medimmune Limited Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
HRP20190366T1 (hr) 2012-10-12 2019-04-19 Medimmune Limited Pirolobenzodiazepini i njihovi konjugati
WO2014057117A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
MX364328B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
PL2906251T3 (pl) 2012-10-12 2018-02-28 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało anty-CD22
CA2891280C (en) 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
RU2019109456A (ru) 2013-02-22 2019-04-10 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые конъюгаты антител и их применения
WO2014140862A2 (en) 2013-03-13 2014-09-18 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
JP6445519B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
ES2523901B1 (es) * 2013-05-31 2015-12-02 Universidad Autónoma de Madrid Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica
WO2015031698A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Site-specific antibody conjugation methods and compositions
JP2016538318A (ja) 2013-08-28 2016-12-08 ステムセントリックス， インコーポレイテッド 新規ｓｅｚ６モジュレーターおよび使用方法
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
PE20160870A1 (es) 2013-11-06 2016-09-09 Abbvie Stemcentrx Llc Anticuerpos anti-claudina novedosos y metodos de uso
KR20160097336A (ko) 2013-12-12 2016-08-17 스템센트알엑스 인코포레이티드 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법
KR20170008202A (ko) 2014-02-21 2017-01-23 애브비 스템센트알엑스 엘엘씨 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
CN106414465B (zh) 2014-02-28 2021-11-16 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
AU2015314954B2 (en) 2014-09-12 2021-05-13 Genentech, Inc. Anti-HER2 antibodies and immunoconjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
WO2015151078A2 (en) 2015-06-15 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Hydrophilic linkers for conjugation
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
NZ741261A (en) 2015-10-02 2019-11-29 Genentech Inc Pyrrolobenzodiazepine antibody drug conjugates and methods of use
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017184942A1 (en) 2016-04-21 2017-10-26 Abbvie Stemcentrx Llc Novel anti-bmpr1b antibodies and methods of use
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CN116143678A (zh) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
UA125198C2 (uk) 2017-02-08 2022-01-26 Ейдісі Терапьютікс Са Кон'югати піролобензодіазепін-антитіло
SI3612537T1 (sl) 2017-04-18 2022-10-28 Medimmune Limited Konjugati pirolobenzodiazepina
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
JP7145891B2 (ja) 2017-06-14 2022-10-03 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ１９ ａｄｃを投与するための投与レジメ
BR112020003003A2 (pt) 2017-08-18 2020-08-11 Medimmune Limited conjugados de pirrolobenzodiazepina
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188378A (en) * 1978-01-04 1980-02-12 The United States Of America As Represented By The Department Of Health, Education And Welfare Anticancer and antiviral activity of 9-β-D-arabinofuranosyl-2-fluoroadenine
CA2341471C (en) * 1998-08-27 2009-04-07 Spirogen Limited Pyrrolbenzodiazepines
GB9818731D0 (en) * 1998-08-27 1998-10-21 Univ Portsmouth Compounds
EP1307459A2 (en) * 2000-08-09 2003-05-07 The Regents of the University of California Indole compounds useful for the treatment of cancer
WO2003072137A1 (en) * 2002-02-28 2003-09-04 Novartis Ag Combinations of (a) an atp- competitive inhibitor of c-abl kinase activity with (b) two or more other antineoplastic agents
WO2005040170A2 (en) * 2003-10-22 2005-05-06 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
FR2869231B1 (fr) 2004-04-27 2008-03-14 Sod Conseils Rech Applic Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine

Also Published As

Publication number Publication date
NO338380B1 (no) 2016-08-15
PT1742644E (pt) 2012-03-02
US8034808B2 (en) 2011-10-11
CY1112387T1 (el) 2015-12-09
FR2869231A1 (fr) 2005-10-28
WO2005105113A2 (fr) 2005-11-10
ES2377066T3 (es) 2012-03-22
EP1742644B1 (fr) 2011-12-28
SI1742644T1 (sl) 2012-03-30
JP2007534730A (ja) 2007-11-29
FR2869231B1 (fr) 2008-03-14
EP1742644A2 (fr) 2007-01-17
US20070232592A1 (en) 2007-10-04
CA2564603C (fr) 2014-07-29
JP5046922B2 (ja) 2012-10-10
NO20065368L (no) 2006-11-21
WO2005105113A3 (fr) 2007-02-22
CA2564603A1 (en) 2005-11-10
DK1742644T3 (da) 2012-04-16
ATE538801T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
SI1742644T1 (sl) Terapevtski sestavek ki vsebuje vsaj en derivat pirolobenzodiazepina in fludarabin
LUC00011I1 (pl)
SG156641A1 (en) Compounds for nonsense suppression, and methods for their use
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
TW200612918A (en) Lonidamine analogs
UA95310C2 (ru) Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
PL1641803T3 (pl) Pochodne tienopirymidyny jako inhibitory kanału potasowego
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007130501A3 (en) Combination therapy for treatment of cancer
IL176227A0 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
HK1101913A (en) Compositions containing beta 2-glycoprotein i for the prevention and/or treatment of vascular disease
HK1117136A (en) Methods and fluorinated compositions for treating amyloid-related diseases